EllumGet notified

GLOW blend: what's in it

By Ellum EditorialPublished Updated AI use

The short answer

GLOW blend combines GHK-Cu, BPC-157 and TB-500.

  • What it is

    Three linear peptides combined in one blend.

  • What people look into

    Muscle and exercise, skin and hair, aging

  • What studies found

    The detailed research on BPC-157 is mostly animal and lab work, and no registered human trial has posted results.[1][2][3]

    Results for one compound don't tell you what the three do together.

The parts

  • GHK-Cu (injectable) Index

    Not FDA-approved

  • BPC-157 Index

    Not FDA-approved · advisory vote July 2026 · no FDA decision

    WADA 2026: S0

    Papers on animals103
    Lab-dish (cell) papers1
    Papers PubMed tags as about people55
    Registered trials (ClinicalTrials.gov)2 of 3 search results name BPC-157
    Randomized trials in peoplenone found

  • TB-500 (thymosin beta-4 fragment LKKTETQ) Index

    Not FDA-approved · advisory vote July 2026 · no FDA decision

    WADA 2026: S2.3

Bars are counts of papers or trials; a longer bar means more studies, not better results. Study counts auto-counted from PubMed tags and ClinicalTrials.gov in the Ellum research database, as of October 6, 2026 (not reviewed; a paper can carry more than one tag). Papers PubMed tags as about people: includes reviews and case reports; not randomized trials. All bars share one scale. Each count is for that part alone.

What studies found

The study findings below come from our BPC-157 page. They are not a review of GHK-Cu, TB-500 or the combination.

Studies of BPC-157 found effects in cells and in rats: in a dish, rat tendon cells moved and spread faster, and in rats, cut Achilles tendons regained strength and alkali skin burns closed sooner.[4][5][6] In a rat model of alkali skin burns, wounds closed faster and showed more collagen and new tissue at day 18 than in controls.[6] The same paper reported that BPC-157 made human umbilical vein cells grow, move and form tube-like structures in a dish.[6] In chick embryo membranes and in dishes of blood-vessel cells, BPC-157 increased vessel density, and in rats with reduced blood flow to a hind leg, blood flow recovered faster and more vessels formed.[7]

Who did the research matters. A 2019 review of soft-tissue studies noted that only a handful of research groups had studied BPC-157 in depth, that most studies used small rodents and that efficacy in humans was yet to be confirmed.[1]

Key point

Most findings on BPC-157 come from rats and cells, and no human trial has posted results yet.[1][2][3]

Safety

The safety notes below come from our BPC-157 page. They are not a safety review of GHK-Cu, TB-500 or the combination.

BPC-157 has two registered Phase 1 trials with a safety aim, one in healthy volunteers and a pilot after rotator cuff surgery, and neither has posted results.[2][3] A 2019 review found few studies reporting adverse reactions, but most studies were in small rodents.[1] Long-term safety in people is unknown.[1][2]

BPC-157 safety detail comes from animal and lab work, and much of it from the group that first described the peptide.[8][9] Rat and lab studies found effects on blood vessels and blood clotting that remain open questions for people.[10][11][12][13] In rats given aspirin, clopidogrel or cilostazol, BPC-157 largely reversed those drugs' effect on platelet clumping.[12] In other rat studies, BPC-157 reduced bleeding time after tail amputation, including in rats given heparin, warfarin or aspirin.[13] Whether these effects occur in people who take blood thinners has not been reported in a human trial.[1][2]

A review from the originating group notes that new vessel growth is also part of tumor biology.[14] The cited animal studies did not test tumor growth.[7][14]

Key point

Long-term effects of BPC-157 in humans are unknown, and no human trial has posted results.[1][2][3]

Regulatory status by component

Not FDA-approved How we label status

  • As of October 4, 2026, GHK-Cu (injectable) is not FDA-approved for any use and is not on FDA's 503A bulks list. See GHK-Cu (injectable) in the Index →
  • As of October 4, 2026, BPC-157 is not FDA-approved. On July 23, 2026, FDA's compounding advisory committee voted to recommend adding it to the 503A bulks list; FDA staff had recommended against it. FDA has not proposed that change. See BPC-157 in the Index →
  • As of October 4, 2026, TB-500 (thymosin beta-4 fragment LKKTETQ) is not FDA-approved. On July 23, 2026, FDA's compounding advisory committee voted to recommend adding it to the 503A bulks list; FDA staff had recommended against it. FDA has not proposed that change. See TB-500 (thymosin beta-4 fragment LKKTETQ) in the Index →

Status as of October 4, 2026

As a combination
Contains GHK-Cu injectable (no category; withdrawn 2026-04-22)
  • GHK-Cu (injectable): as of October 4, 2026 · source
  • BPC-157: as of October 4, 2026 · source
  • TB-500 (thymosin beta-4 fragment LKKTETQ): as of October 4, 2026 · source

Timeline

Scroll sideways to see all columns.

DateWhat happenedSource
U.S. Attorney's Office for the District of Utah press release on an indictment lists GHK-CU, BPC-157 and TB500 among peptides allegedly obtained from China and sold to patients.Government source
FDA lists GHK-Cu (injectable routes), BPC-157 and thymosin beta-4 fragment (LKKTETQ), also known as TB-500, among bulk drug substances nominated but withdrawn (previously in category 2, withdrawn by the nominators) on its page of bulk drug substances that may present significant safety risks in compounding (content current as of 2026-04-22).FDA

Get updates on GLOW blend (GHK-Cu + BPC-157 + TB-500)

We'll store your email, your state, the page you're on and the peptides selected below (pre-selected from this page; untick any). Together these can reveal health interests. We use them only for what you tick below and to count sign-ups by state and peptide, without emails, to plan where the clinic opens and for reports that show only totals. Our hosting, database and email providers handle them for us. We pass them to a doctor or clinic only if you tick that box, and we don't sell them. Withdraw anytime with the unsubscribe link or at hello@ellumclinic.com. Consumer Health Data Privacy Policy

Ellum's sign-ups are for adults 18 and over.

Peptides: GLOW blend (GHK-Cu + BPC-157 + TB-500) (1 selected) · edit
Peptides you're interested in
What we may email you about
More options (optional): research, doctor contact, paid offers

The research on GLOW blend (GHK-Cu + BPC-157 + TB-500)

Key facts

Also known as: glow peptide, glow stack, glow peptide blend

Parts
GHK-Cu (injectable), BPC-157 and TB-500 (thymosin beta-4 fragment LKKTETQ)
Route
injectable

References

  1. pubmed.ncbi.nlm.nih.gov/30915550
  2. clinicaltrials.gov/study/NCT02637284
  3. clinicaltrials.gov/study/NCT07803250
  4. pubmed.ncbi.nlm.nih.gov/21030672
  5. pubmed.ncbi.nlm.nih.gov/14554208
  6. pubmed.ncbi.nlm.nih.gov/25995620
  7. pubmed.ncbi.nlm.nih.gov/27847966
  8. pubmed.ncbi.nlm.nih.gov/23755725
  9. pubmed.ncbi.nlm.nih.gov/22950504
  10. pubmed.ncbi.nlm.nih.gov/33051481
  11. pubmed.ncbi.nlm.nih.gov/9298922
  12. pubmed.ncbi.nlm.nih.gov/31976029
  13. pubmed.ncbi.nlm.nih.gov/21840572
  14. pubmed.ncbi.nlm.nih.gov/23782145
  15. pubmed.ncbi.nlm.nih.gov/9403788

Status sources

Sources as of October 4, 2026

  1. FDA: www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
  2. FDA: www.fda.gov/media/94155/download
  3. WADA: www.wada-ama.org/sites/default/files/2025-09/2026list_en_final_clean_september_2025.pdf

What this doesn’t establish

Results for one compound don't tell you what the three do together.

The BPC-157 evidence does not establish that any effect seen in rats, chickens or lab cells happens in people.[1][15] A 2019 review states that efficacy is yet to be confirmed in humans, so no benefit for any condition in people has been shown.[1]